Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
作者信息
Srour S A, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall E J, Wierda W G, Kantarjian H, Champlin R E, Cooper L J, Kebriaei P
机构信息
Department of Stem Cell Transplantation and Cellular Therapy and.
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood. 2020 Mar 12;135(11):862-865. doi: 10.1182/blood.2019002920.
Abstract
摘要
相似文献
1
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
Blood. 2020 Mar 12;135(11):862-865. doi: 10.1182/blood.2019002920.
2
Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:446-453. doi: 10.1200/EDBK_238693. Epub 2019 May 17.
3
Updates on CAR T-cell therapy in B-cell malignancies.
Immunol Rev. 2019 Jul;290(1):39-59. doi: 10.1111/imr.12774.
4
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
5
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
Leukemia. 2019 Dec;33(12):2767-2778. doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5.
6
Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Leuk Lymphoma. 2019 Jun;60(6):1454-1461. doi: 10.1080/10428194.2018.1533127. Epub 2019 Feb 4.
7
Challenges of driving CD30-directed CAR-T cells to the clinic.
BMC Cancer. 2019 Mar 6;19(1):203. doi: 10.1186/s12885-019-5415-9.
8
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
9
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Int J Mol Sci. 2019 May 18;20(10):2469. doi: 10.3390/ijms20102469.
10
Managing the toxicities of CAR T-cell therapy.
Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595.
引用本文的文献
1
Safety and Efficacy of CD19-Targeted Chimeric Antigen Receptor (CAR) T-cells Generated Using DNA Transposon Systems: A Meta-Analysis.
Cureus. 2025 Apr 8;17(4):e81930. doi: 10.7759/cureus.81930. eCollection 2025 Apr.
2
Cost-effective strategies for CAR-T cell therapy manufacturing.
Mol Ther Oncol. 2025 Apr 3;33(2):200980. doi: 10.1016/j.omton.2025.200980. eCollection 2025 Jun 18.
3
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.
Exp Hematol Oncol. 2024 Dec 4;13(1):118. doi: 10.1186/s40164-024-00583-7.
4
Updates in Immunotherapy for Pancreatic Cancer.
J Clin Med. 2024 Oct 26;13(21):6419. doi: 10.3390/jcm13216419.
5
TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.
J Transl Med. 2024 Oct 4;22(1):897. doi: 10.1186/s12967-024-05703-9.
6
Empowering virus-free CAR immune cell therapies.
Mol Ther. 2024 Jun 5;32(6):1609-1611. doi: 10.1016/j.ymthe.2024.05.023. Epub 2024 May 25.
7
A Naturally Active Spy Transposon Discovered from the Insect Genome of Colletes gigas as a Promising Novel Gene Transfer Tool.
Adv Sci (Weinh). 2024 Aug;11(29):e2400969. doi: 10.1002/advs.202400969. Epub 2024 May 22.
8
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.
Mol Ther. 2024 Jun 5;32(6):1817-1834. doi: 10.1016/j.ymthe.2024.04.024. Epub 2024 Apr 16.
9
Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer.
J Transl Med. 2024 Feb 18;22(1):171. doi: 10.1186/s12967-024-04982-6.
10
Microphysiological systems for solid tumor immunotherapy: opportunities and challenges.
Microsyst Nanoeng. 2023 Dec 15;9:154. doi: 10.1038/s41378-023-00616-x. eCollection 2023.
本文引用的文献
1
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.
2
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
3
Novel therapies for relapsed/refractory aggressive lymphomas.
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):75-82. doi: 10.1182/asheducation-2018.1.75.
4
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
5
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
6
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Br J Haematol. 2017 Aug;178(4):561-570. doi: 10.1111/bjh.14731. Epub 2017 May 9.
7
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.
8
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.
9
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.
10
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
Zotero 插件